{
"id":"mk19_b_pm_s3",
"subspecialtyId":"pm",
"title":"Diffuse Parenchymal Lung Disease",
"jsonContent":{
"type":"section",
"id":"mk19_b_pm_s3",
"title":{
"__html":"Diffuse Parenchymal Lung Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"02e678",
"children":[
"Diffuse Parenchymal Lung Disease"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s3_0",
"children":[
{
"type":"p",
"hlId":"728da6",
"children":[
"Diffuse parenchymal lung diseases (DPLDs) are a diverse group of nonmalignant disorders resulting in the inflammation and scarring of alveolar structures. These disorders tend to mimic each other clinically and radiographically."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_1",
"title":{
"__html":"Classification and Epidemiology"
},
"titleNode":{
"type":"section-title",
"hlId":"17f49d",
"children":[
"Classification and Epidemiology"
]
},
"children":[
{
"type":"p",
"hlId":"eb2241",
"children":[
"Typically, DPLDs are classified into those with a known cause and those that are idiopathic ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t15",
"wrapId":"1",
"children":[
"Table 15"
]
}
]
},
")"
]
},
". This classification has implications for management strategies and prognosis. The prevalence of DPLDs is estimated to be approximately 70 per 100,000 persons."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_pm_t15"
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_2",
"title":{
"__html":"Diagnostic Approach and Evaluation"
},
"titleNode":{
"type":"section-title",
"hlId":"050f29",
"children":[
"Diagnostic Approach and Evaluation"
]
},
"children":[
{
"type":"p",
"hlId":"038127",
"children":[
"The most common presentation of a DPLD is subacute to chronic exertional dyspnea and nonproductive cough. History should include a thorough review of potential exposures, including occupations, home environment, hobbies, and current and past medications, as well as over-the-counter supplements. A history of radiation therapy, a family history of lung disease or connective tissue disease (CTD), and suggestive symptoms of CTD should be explored."
]
},
{
"type":"p",
"hlId":"91b7ec",
"children":[
"Lung examination findings can range from a normal auscultatory examination to the presence of inspiratory Velcro crackles or an inspiratory squawk suggestive of fibrosis. Extrapulmonary examination findings of associated CTD, such as joint deformities or Gottron papules, may direct the clinician to the cause of the DPLD. Advanced disease may be complicated by pulmonary hypertension and cor pulmonale, with examination findings of jugular venous distention, peripheral edema, and a pronounced pulmonic component of the second heart sound."
]
},
{
"type":"p",
"hlId":"bb5541",
"children":[
"It is common for patients with DPLD to have normal resting pulse oximetry. Desaturation of greater than 4% with ambulation is consistent with a diffusion limitation, which is a hallmark of DPLD."
]
},
{
"type":"p",
"hlId":"13328e",
"children":[
"Typically, bilateral diffuse reticular and reticulonodular patterns on chest radiography suggest DPLD. The presence of consolidation, pleural effusions, pleural calcification, bronchiectasis, or lymphadenopathy may provide clues to discrete etiologies for DPLD. Chest radiograph can be normal in patients with minimal disease, and a normal chest radiograph does not rule out DPLD."
]
},
{
"type":"p",
"hlId":"443026",
"children":[
"Patients for whom a DPLD is suspected should undergo complete pulmonary function testing, including lung volume testing with plethysmography or nitrogen diffusion and D",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"LCO"
]
},
" measurement. The vast majority of DPLDs have restrictive physiology, although some diseases may exhibit obstructive or mixed obstructive and restrictive deficits."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"88a61f",
"children":[
"The most common presentation of a diffuse parenchymal lung disease is subacute to chronic exertional dyspnea and nonproductive cough."
]
},
{
"type":"keypoint",
"hlId":"622994",
"children":[
"Patients with a clinical suspicion of diffuse parenchymal lung disease should undergo complete pulmonary function testing, including lung volumes and D",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"LCO"
]
},
" measurement."
]
},
{
"type":"keypoint",
"hlId":"d427ef",
"children":[
"A normal chest radiograph does not rule out DPLD."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_2_1",
"title":{
"__html":"High-Resolution CT Scanning"
},
"titleNode":{
"type":"section-title",
"hlId":"908784",
"children":[
"High-Resolution CT Scanning"
]
},
"children":[
{
"type":"p",
"hlId":"a6477a",
"children":[
"Noncontrast high-resolution CT (HRCT) of the chest is the imaging modality of choice for evaluation of DPLD. Distribution of disease and pattern of pulmonary parenchyma involvement may suggest the underlying diagnosis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t16",
"wrapId":"2",
"children":[
"Table 16"
]
}
]
},
")"
]
},
". Addition of expiratory images to accentuate air trapping can elucidate small airways disease. Prone images may be helpful to distinguish subpleural reticular opacities and septal thickening from dependent atelectasis."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_pm_t16"
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_2_2",
"title":{
"__html":"Serologic Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"775a60",
"children":[
"Serologic Testing"
]
},
"children":[
{
"type":"p",
"hlId":"176482",
"children":[
"For patients with newly detected DPLD of apparently unknown cause who are clinically suspected of having idiopathic pulmonary fibrosis, the American Thoracic Society guidelines recommend serologic testing to exclude CTD-associated DPLD. Routine testing with C-reactive protein, erythrocyte sedimentation rate, antinuclear antibodies, rheumatoid factor, myositis panel, and anti–cyclic citrullinated peptide antibodies is recommended. See ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s1_6_2",
"children":[
"MKSAP 19 Rheumatology"
]
},
" for further discussion of testing for connective tissue disease."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_2_3",
"title":{
"__html":"Lung Biopsy"
},
"titleNode":{
"type":"section-title",
"hlId":"b6d201",
"children":[
"Lung Biopsy"
]
},
"children":[
{
"type":"p",
"hlId":"f66b23",
"children":[
"When pulmonary function tests and HRCT are insufficient for making the diagnosis, the physician must consider a bronchoscopic or surgical lung biopsy. Careful assessment of risk factors, alternate diagnostic strategies, and effect of the results of lung biopsy on treatment should be discussed within a multidisciplinary team, including a thoracic radiologist, thoracic surgeon, and pulmonary specialist with expertise in DPLD."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"ca0e36",
"children":[
"Noncontrast high-resolution CT scan of the chest is the imaging modality of choice for evaluation of diffuse parenchymal lung disease."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_3",
"title":{
"__html":"Diffuse Parenchymal Lung Diseases With a Known Cause"
},
"titleNode":{
"type":"section-title",
"hlId":"a1abfe",
"children":[
"Diffuse Parenchymal Lung Diseases With a Known Cause"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s3_3_1",
"title":{
"__html":"Smoking-Related Diffuse Parenchymal Lung Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"dda426",
"children":[
"Smoking-Related Diffuse Parenchymal Lung Disease"
]
},
"children":[
{
"type":"p",
"hlId":"68dc7a",
"children":[
"DPLDs that occur almost exclusively in individuals who are current smokers include respiratory bronchiolitis-associated interstitial lung disease (RB-ILD); desquamative interstitial pneumonia (DIP), a more severe form of smoking-related DPLD; pulmonary Langerhans cell histiocytosis (PLCH); and smoking-related interstitial fibrosis (SRIF). Smoking in conjunction with other endogenous or exogenous factors may also contribute to IPF as well as combined pulmonary fibrosis and emphysema."
]
},
{
"type":"p",
"hlId":"3f6d21",
"children":[
"Typical findings on HRCT include ground-glass opacities with fine centrilobular nodules in RB-ILD, diffuse ground-glass opacification with lower zone predominance in DIP, and diffuse thin-walled cysts and nodular lesions in upper and mid lung zones in PLCH. Patients with PLCH also have a predilection to recurrent pneumothoraces. Demonstrating abnormal numbers of Langerhans cells with S100 or CD1a staining in bronchoalveolar lavage fluid or on tissue obtained by either transbronchial or open lung biopsy confirms the diagnosis."
]
},
{
"type":"p",
"hlId":"d9a8cb",
"children":[
"SRIF is an entity that radiologically mimics RB-ILD. However, it is pathologically distinct, with deposition of hyalinized collagen in alveolar septa and minimal inflammation."
]
},
{
"type":"p",
"hlId":"2ed595",
"children":[
"On physiologic testing, patients with any smoking-related DPLD will have a reduced D",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"LCO"
]
},
". RB-ILD and SRIF may have combined restriction and obstruction, whereas DIP typically is associated with pure restrictive disease. PLCH often produces restrictive disease but may have preserved total lung capacity and evidence of obstruction when significant cystic disease is present. COPD is a common comorbidity that may add an obstructive component to testing in any patient who smokes."
]
},
{
"type":"p",
"hlId":"310834",
"children":[
"For all smoking-related DPLDs, the primary management is smoking cessation. Glucocorticoids may be considered with severe disease or in those with refractory symptoms."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"a1a109",
"children":[
"The primary management of all smoking-related DPLDs is smoking cessation."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_3_2",
"title":{
"__html":"Connective Tissue Diseases"
},
"titleNode":{
"type":"section-title",
"hlId":"5efe25",
"children":[
"Connective Tissue Diseases"
]
},
"children":[
{
"type":"p",
"hlId":"00890e",
"children":[
"Immune-mediated injury from underlying connective tissue disease can result in DPLD. Typically manifesting in patients with an established CTD, lung disease can occasionally arise before the development of extrapulmonary findings. Younger patients who present with DPLD have a higher prevalence of CTD. CTD-related DPLDs encompass all major HRCT patterns of DPLD ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t17",
"wrapId":"3",
"children":[
"Table 17"
]
}
]
},
")"
]
},
". Nonspecific interstitial pneumonia is more common than usual interstitial pneumonia (UIP) in patients with CTD. Furthermore, patients with CTD treated with doses of methotrexate greater than 15 mg/wk, and sometimes other agents, may be at risk for drug-induced DPLD."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_pm_t17"
]
},
{
"type":"p",
"hlId":"d4a54b",
"children":[
"One syndrome in patients with CTD–ILD that warrants particular attention is the antisynthetase syndrome. This syndrome presents as polymyositis or dermatomyositis with radiographic evidence of ILD in combination with one or more anti-aminoacyl-tRNA synthetase antibodies. Patients may not have overt signs of systemic disease; however, ILD may be severe and rapidly progressive. See ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s9_5_3",
"children":[
"MKSAP 19 Rheumatolog"
]
},
"y for further discussion of antisynthetase syndrome."
]
},
{
"type":"p",
"hlId":"e24485",
"children":[
"Glucocorticoids and immunomodulatory therapy with agents such as mycophenolate mofetil, methotrexate, cyclophosphamide, and rituximab may be used in consultation with rheumatology and pulmonary specialists."
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_3_3",
"title":{
"__html":"Hypersensitivity Pneumonitis"
},
"titleNode":{
"type":"section-title",
"hlId":"a75f83",
"children":[
"Hypersensitivity Pneumonitis"
]
},
"children":[
{
"type":"p",
"hlId":"bca08f",
"children":[
"Repetitive inhalation of specific antigens in a sensitized patient can result in hypersensitivity pneumonitis (HP), an immunologic response that results in noncaseating granulomas and peribronchial mononuclear cell and giant cell inflammation. The antigens are typically complex proteins that can come from several sources, including agricultural dusts, thermophilic fungi, and bacteria, but they can also be low-molecular-weight organic compounds. There are three forms of HP, and each presents differently. The acute form, which is the most easily identified form, results after a large exposure to an inciting antigen. The patient typically develops fever, cough, and fatigue within 12 hours of exposure. Chest radiography can demonstrate diffuse micronodular disease but may be normal. Physical examination will reveal inspiratory crackles. If HRCT is performed, it will demonstrate diffuse centrilobular micronodules and ground-glass opacities ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f05",
"wrapId":"4",
"children":[
"Figure 5"
]
}
]
},
")"
]
},
". After removal from the offending antigen, symptoms usually resolve within approximately 48 hours. Recurrence of symptoms if the patient is rechallenged is the hallmark of the disease."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_pm_f05"
]
},
{
"type":"p",
"hlId":"906680",
"children":[
"Subacute and chronic forms of HP occur after more prolonged lower-level antigen exposure. “Bird fancier's lung disease” is an example of a chronic disorder caused by inhalation of avian proteins from feathers, skin, or guano. These patients experience cough, fatigue, weight loss, and shortness of breath. As in the acute form, the HRCT scan will show micronodules and ground-glass opacities, but there is also evidence of septal thickening and fibrosis. In the disease's most severe and chronic form, significant traction bronchiectasis and honeycomb changes will be evident. Evidence of severe fibrosis on CT imaging significantly increases the risk for disease progression and death."
]
},
{
"type":"p",
"hlId":"2586c5",
"children":[
"Removal of exposure to the offending antigen is essential in the treatment of HP. To identify potential antigens, a careful history is vital, as serologic testing is often limited and may not include antibodies to the responsible antigen. Glucocorticoids and sometimes other immunosuppressants are often used for those with more severe symptoms."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0ef95f",
"children":[
"Removal of exposure to the offending antigen is essential in the treatment of hypersensitivity pneumonitis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_3_4",
"title":{
"__html":"Drug-Induced Diffuse Parenchymal Lung Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"317b68",
"children":[
"Drug-Induced Diffuse Parenchymal Lung Disease"
]
},
"children":[
{
"type":"p",
"hlId":"a1eadb",
"children":[
"Many medications have been implicated in the development of DPLD ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t18",
"wrapId":"5",
"children":[
"Table 18"
]
}
]
},
")"
]
},
". Duration of exposure to the development of disease can vary, even for the same agent. For instance, amiodarone lung toxicity has an acute form presenting with acute lung injury/acute respiratory distress syndrome, as well as a chronic indolent form with reticular abnormalities and subpleural nodules. Prompt treatment by removal of the offending agent is important for resolution of symptoms. For those with more severe symptoms, glucocorticoids may have some benefit, although data are anecdotal."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_pm_t18"
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_3_5",
"title":{
"__html":"Radiation Pneumonitis"
},
"titleNode":{
"type":"section-title",
"hlId":"41e8e2",
"children":[
"Radiation Pneumonitis"
]
},
"children":[
{
"type":"p",
"hlId":"c4536c",
"children":[
"Radiation pneumonitis typically occurs 4 to 12 weeks after radiation exposure. Patients present with cough, shortness of breath, and radiographic infiltrates. Fever, pleuritic chest pain, fatigue, and weight loss are accompanying nonspecific symptoms. Differential diagnosis often includes infection and drug-induced lung injury. On imaging, a well-defined nonanatomic demarcation between normal and abnormal lung consistent with the radiation field is pathognomonic but not always present. Other lung abnormalities, such as organizing pneumonia, may also be observed outside the field of exposure. Observation may be appropriate for those with mild disease. Glucocorticoids are used for patients with severe symptoms or hypoxemia. From 6 to 12 months after radiation exposure, additional findings on HRCT may develop, including septal thickening, traction bronchiectasis, and volume loss consistent with chronic fibrosis. Individuals exposed to radiation are also at risk for the development of radiation recall pneumonitis, which can occur when lung tissue is subsequently exposed to certain immune checkpoint inhibitors and chemotherapy agents, including doxorubicin, etoposide, gemcitabine, paclitaxel, and pemetrexed, which trigger pathologic changes in the lung tissue previously exposed to radiation."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"6782ec",
"children":[
"Radiation pneumonitis typically presents 4 to 12 weeks after initial radiation exposure with cough, shortness of breath, and a new radiographic infiltrate."
]
},
{
"type":"keypoint",
"hlId":"869d16",
"children":[
"Treatment of severe forms of radiation pneumonitis typically is glucocorticoids, whereas observation may be appropriate for those with mild disease."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_4",
"title":{
"__html":"Diffuse Parenchymal Lung Diseases With an Unknown Cause"
},
"titleNode":{
"type":"section-title",
"hlId":"a4f469",
"children":[
"Diffuse Parenchymal Lung Diseases With an Unknown Cause"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_pm_s3_4_1",
"title":{
"__html":"Idiopathic Pulmonary Fibrosis"
},
"titleNode":{
"type":"section-title",
"hlId":"8b4782",
"children":[
"Idiopathic Pulmonary Fibrosis"
]
},
"children":[
{
"type":"p",
"hlId":"bf396b",
"children":[
"Idiopathic pulmonary fibrosis (IPF), which is associated with the histopathologic pattern of UIP, is the most common idiopathic form of DPLD. Deemed to be a reflection of dysregulated fibrosis in response to alveolar epithelial injury, it typically presents with chronic cough and dyspnea in patients between 50 and 70 years of age. Lung examination is notable for bibasilar Velcro-like inspiratory crackles. Clubbing is present in up to 50% of patients. Smoking is considered a risk factor, and patients are often treated for COPD without significant improvement. Chest radiographs may demonstrate bibasilar reticular changes. Characteristic HRCT abnormalities include bilateral, subpleural, and basal predominant reticular changes. Advanced cases may develop traction bronchiectasis with subpleural clusters of palisading cysts called honeycombing ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f06",
"wrapId":"6",
"children":[
"Figure 6"
]
}
]
},
")"
]
},
". When HRCT findings are classic for UIP, lung biopsy is not necessary for diagnosis."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_pm_f06"
]
},
{
"type":"p",
"hlId":"5ffc66",
"children":[
"IPF is progressive, with a median survival of 3 to 5 years after diagnosis. Patients may experience acute exacerbations with a rapid worsening of symptoms and development of bilateral ground-glass opacities superimposed on areas of background fibrosis. These events may represent an acceleration of the disease. Even though glucocorticoids and antibiotics are frequently used, there are no proven therapies for acute exacerbations of IPF."
]
},
{
"type":"p",
"hlId":"488f5b",
"children":[
"Management of patients with IPF should include consideration of antifibrotic therapies and oxygen supplementation for hypoxemia. In 2014 the FDA approved nintedanib, a tyrosine kinase inhibitor, and pirfenidone, an antifibrotic agent, for use in patients with IPF. Although the mechanisms of these two medications differ, the clinical response is quite similar, with both demonstrating a decline in the rate of progression of disease. Although these medications delay IPF progression, they are not curative. Referral to a pulmonologist or ILD center is appropriate before initiating treatment with these medications."
]
},
{
"type":"p",
"hlId":"601bda",
"children":[
"Given the progressive and unpredictable clinical course of IPF, early referral to a lung transplant center is strongly recommended."
]
},
{
"type":"p",
"hlId":"ae4810",
"children":[
"Palliative care consultation to establish advanced care plans should be considered for patients with IPF who are not candidates for lung transplantation."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0f0812",
"hvc":true,
"children":[
"When high-resolution CT findings are classic for usual interstitial pneumonia, lung biopsy is not necessary for diagnosis."
]
},
{
"type":"keypoint",
"hlId":"19b845",
"children":[
"Therapy with nintedanib and pirfenidone decreases the rate of progression of idiopathic pulmonary fibrosis but is not curative."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_4_2",
"title":{
"__html":"Nonspecific Interstitial Pneumonia"
},
"titleNode":{
"type":"section-title",
"hlId":"a40f83",
"children":[
"Nonspecific Interstitial Pneumonia"
]
},
"children":[
{
"type":"p",
"hlId":"d0056c",
"children":[
"Although nonspecific interstitial pneumonia (NSIP) is a common variant in CTD-associated DPLD, idiopathic NSIP is a distinct clinical entity. Differentiation of idiopathic NSIP from IPF is critical as the two diseases have distinct treatment algorithms and IPF has a worse prognosis. NSIP typically affects a younger population than IPF. The HRCT scan typically demonstrates bilateral lower-lobe reticular changes and scattered ground-glass opacities ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f07",
"wrapId":"7",
"children":[
"Figure 7"
]
}
]
},
")"
]
},
". Although NSIP can progress to fibrosis, honeycombing, which is a classic feature for UIP, is rarely seen in NSIP. Biopsy is frequently warranted to confirm the diagnosis and exclude alternate pathologies and may reveal inflammation and fibrosis. On the basis of the extent of inflammation and fibrosis, cellular and fibrotic forms of NSIP are described. The cellular form has a better prognosis and typically responds to immunosuppressive treatments. Although the overall prognosis is better than for IPF, the 5-year mortality of idiopathic NSIP remains approximately 15% to 25%. As with IPF, selected patients may benefit from lung transplantation."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_pm_f07"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"5f247a",
"children":[
"On high-resolution CT, nonspecific interstitial pneumonia typically demonstrates bilateral lower-lobe reticular changes and areas of ground-glass opacification."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_4_3",
"title":{
"__html":"Cryptogenic Organizing Pneumonia"
},
"titleNode":{
"type":"section-title",
"hlId":"260a15",
"children":[
"Cryptogenic Organizing Pneumonia"
]
},
"children":[
{
"type":"p",
"hlId":"df69b9",
"children":[
"Organizing pneumonia is defined by histopathologic findings of patchy proliferation of granulation tissue that affects the terminal bronchioles and alveolar ducts and spaces and is associated with surrounding inflammation. This pattern is nonspecific and often follows or is associated with various types of injury to the lung, including acute infection, radiation exposure, drug-induced pneumonitis, and autoimmune diseases. In patients in whom no cause is identified, the diagnosis is termed cryptogenic organizing pneumonia (COP)."
]
},
{
"type":"p",
"hlId":"361803",
"children":[
"Patients with COP typically have a subacute presentation with cough, fever, and malaise over weeks to months. Initial chest radiographs typically demonstrate patchy opacities that mimic pneumonia, and as a result, patients are often initially misdiagnosed with pneumonia and treated with antibiotics ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f08",
"wrapId":"8",
"children":[
"Figure 8"
]
}
]
},
")"
]
},
". However, nonresolving symptoms and failure to respond to antibiotics should raise suspicion for organizing pneumonia or COP. HRCT findings can range from ground-glass opacities to areas of alveolar consolidation resembling an infectious pneumonia. The diagnosis may not require lung biopsy if the clinical presentation and HRCT findings are consistent with COP. For cases with atypical presentation, lung biopsy helps make the diagnosis."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_pm_f08"
]
},
{
"type":"p",
"hlId":"ac385f",
"children":[
"Patients with COP respond well to glucocorticoid therapy. Relapses of COP with tapering of glucocorticoids are common. In such settings, consideration of glucocorticoid-sparing therapies is warranted."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"6089e9",
"children":[
"Cryptogenic organizing pneumonia typically presents as cough, fever, and malaise lasting weeks to months, and imaging findings mimic infectious pneumonia; treatment is with glucocorticoids."
]
},
{
"type":"keypoint",
"hlId":"fbf803",
"hvc":true,
"children":[
"The diagnosis of cryptogenic organizing pneumonia (COP) may not require lung biopsy if the clinical presentation and high-resolution CT findings are consistent with COP; for cases with atypical presentation, lung biopsy helps make the diagnosis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_4_4",
"title":{
"__html":"Acute Interstitial Pneumonia"
},
"titleNode":{
"type":"section-title",
"hlId":"90003c",
"children":[
"Acute Interstitial Pneumonia"
]
},
"children":[
{
"type":"p",
"hlId":"28c776",
"children":[
"Acute interstitial pneumonia develops rapidly over days to weeks, resulting in acute respiratory failure with bilateral alveolar opacities on HRCT of the chest. The pathologic findings on open lung biopsy are those of diffuse alveolar damage. This process is clinically, radiographically, and pathologically indistinguishable from acute respiratory distress syndrome (ARDS). The absence of known risk factors for the development of ARDS suggests a diagnosis of acute interstitial pneumonia."
]
},
{
"type":"p",
"hlId":"1ce503",
"children":[
"Management includes ventilatory support and critical care, as it does for patients with ARDS. Mortality remains high (approximately 50%), and those who recover from the initial illness often have complications, are at risk for the development of chronic lung disease, and may have a relapse. Patients are often treated with high-dose glucocorticoids, although strong evidence to support their use is lacking."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8e89ce",
"children":[
"Acute interstitial pneumonia is clinically, radiographically, and pathologically indistinguishable from acute respiratory distress syndrome (ARDS), but patients lack risk factors for ARDS."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_4_5",
"title":{
"__html":"Combined Pulmonary Fibrosis and Emphysema"
},
"titleNode":{
"type":"section-title",
"hlId":"de5200",
"children":[
"Combined Pulmonary Fibrosis and Emphysema"
]
},
"children":[
{
"type":"p",
"hlId":"3aedf7",
"children":[
"Combined pulmonary fibrosis and emphysema (CPFE) is a distinct clinical entity wherein fibrotic lung disease, similar to IPF, coexists with emphysematous changes in the same patient ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f09",
"wrapId":"9",
"children":[
"Figure 9"
]
}
]
},
")"
]
},
". Even with advanced architectural changes, lung function studies may reveal preserved spirometry and lung volumes. Marked impairment in gas exchange manifesting as reduced diffusing capacity is typical for CPFE. Presence of pulmonary hypertension in patients with CPFE portends a poor prognosis. Lung transplant is the only curative therapy."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_pm_f09"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_5",
"title":{
"__html":"Sarcoidosis"
},
"titleNode":{
"type":"section-title",
"hlId":"c57e04",
"children":[
"Sarcoidosis"
]
},
"children":[
{
"type":"p",
"hlId":"633d50",
"children":[
"Sarcoidosis is a granulomatous disease of unknown cause that can affect any organ system. More than 90% of patients with sarcoidosis have lung involvement. The prevalence of sarcoidosis is approximately 10 to 20 per 100,000 individuals. Many patients are asymptomatic, and lung involvement is incidentally found on chest radiography performed for other reasons ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_pm_f10",
"wrapId":"10",
"children":[
"Figure 10"
]
}
]
},
")"
]
},
". Findings from chest radiography can help predict the probability of spontaneous resolution ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t19",
"wrapId":"10",
"children":[
"Table 19"
]
}
]
},
")"
]
},
". CT scanning can show pulmonary parenchymal disease or intrathoracic lymphadenopathy, either alone or in combination. Presence of nodules along bronchovascular bundles on HRCT imaging suggests sarcoidosis as the cause of the disease."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_pm_f10",
"mk19_b_pm_t19"
]
},
{
"type":"p",
"hlId":"1cb02e",
"children":[
"Pulmonary function testing is typically abnormal and findings can be obstructive, restrictive, or both. Sarcoidosis is a diagnosis of exclusion. Diagnosis, with a few exceptions ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t20",
"wrapId":"11",
"children":[
"Table 20"
]
}
]
},
")"
]
},
", typically requires bronchoscopic biopsy, with tissue obtained from a lymph node or from the pulmonary parenchyma. The diagnosis is made by the finding of noncaseating granulomas with exclusion of potential mimicking infections (mycobacteria, fungi), exclusion of other systemic granulomatous diseases, and ideally involvement of more than one organ system."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_pm_t20"
]
},
{
"type":"p",
"hlId":"a5df94",
"children":[
"Development of pulmonary hypertension in patients with sarcoidosis is a poor prognostic indicator, with a median survival of approximately 3 years."
]
},
{
"type":"p",
"hlId":"f0addb",
"children":[
"The primary treatment of sarcoidosis is glucocorticoids, although many patients do not need to be treated. In addition, spontaneous resolution without treatment is common and is related to the radiographic stage of disease (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_pm_t19",
"wrapId":"12",
"children":[
"Table 19"
]
}
]
},
")"
]
},
". The decision to treat and assessment of response to treatment should be based on symptoms and organ dysfunction, not radiographic findings. For those without symptoms or organ dysfunction, observation is appropriate. If treatment is required, glucocorticoid therapy is appropriate. For patients with more severe or prolonged symptoms, adverse effects from chronic glucocorticoids should be considered. In this setting, adjunctive glucocorticoid-sparing therapies are often used. Pulmonary consultation should be considered for management of persistent disease. For patients with pulmonary hypertension or severe disease with significant activity limitation resulting from lung impairment, evaluation for lung transplantation is appropriate."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_pm_t19"
]
},
{
"type":"p",
"hlId":"8af361",
"children":[
"For nonpulmonary manifestations of sarcoidosis, see ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s15_5",
"children":[
"MKSAP 19 Rheumatology"
]
},
"."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"7e6f7b",
"children":[
"More than 90% of patients with sarcoidosis have lung involvement; radiographic staging can predict the probability of spontaneous resolution."
]
},
{
"type":"keypoint",
"hlId":"f0dbe0",
"children":[
"The primary treatment of symptomatic sarcoidosis is glucocorticoids, often followed by glucocorticoid-sparing therapies."
]
},
{
"type":"keypoint",
"hlId":"2bcb59",
"children":[
"Löfgren syndrome consists of erythema nodosum, arthritis, fever, and hilar lymphadenopathy; a biopsy is not needed to confirm the diagnosis."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_pm_s3_6",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. Respirology. 2016;21:259-68. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26564810",
"target":"_blank"
},
"children":[
"PMID: 26564810"
]
},
" doi:10.1111/resp.12674"
]
},
{
"type":"reference",
"children":[
"Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report. Am J Respir Crit Care Med. 2016;194:265-75. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27299520",
"target":"_blank"
},
"children":[
"PMID: 27299520"
]
},
" doi:10.1164/rccm.201604-0801CI"
]
},
{
"type":"reference",
"children":[
"Kumar A, Cherian SV, Vassallo R, et al. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest. 2018;154:394-408. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29222007",
"target":"_blank"
},
"children":[
"PMID: 29222007"
]
},
" doi:10.1016/j.chest.2017.11.023"
]
},
{
"type":"reference",
"children":[
"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811-1823. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29742380",
"target":"_blank"
},
"children":[
"PMID: 29742380"
]
},
" doi:10.1056/NEJMra1705751"
]
},
{
"type":"reference",
"children":[
"Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc. 2019;94:309-325. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30558827",
"target":"_blank"
},
"children":[
"PMID: 30558827"
]
},
" doi:10.1016/j.mayocp.2018.09.002"
]
},
{
"type":"reference",
"children":[
"Noe MH, Rosenbach M. Cutaneous sarcoidosis. Curr Opin Pulm Med. 2017;23:482-486. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28598873",
"target":"_blank"
},
"children":[
"PMID: 28598873"
]
},
" doi:10.1097/MCP.0000000000000402"
]
},
{
"type":"reference",
"children":[
"Raghu G, Remy-Jardin M, Myers JL, et al; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44-e68. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30168753",
"target":"_blank"
},
"children":[
"PMID: 30168753"
]
},
" doi:10.1164/rccm.201807-1255ST"
]
},
{
"type":"reference",
"children":[
"Raghu G, Rochwerg B, Zhang Y, et al; American Thoracic Society. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3-19. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26177183",
"target":"_blank"
},
"children":[
"PMID: 26177183"
]
},
" doi:10.1164/rccm.201506-1063ST"
]
},
{
"type":"reference",
"children":[
"Tomassetti S, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. Eur Respir Rev. 2017;26. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28446601",
"target":"_blank"
},
"children":[
"PMID: 28446601"
]
},
" doi:10.1183/16000617.0004-2017"
]
},
{
"type":"reference",
"children":[
"Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016;23:218-226. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27594777",
"target":"_blank"
},
"children":[
"PMID: 27594777"
]
}
]
},
{
"type":"reference",
"children":[
"Yoon HY, Kim TH, Seo JB, et al. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology. 2019;24:55-62. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30136753",
"target":"_blank"
},
"children":[
"PMID: 30136753"
]
},
" doi:10.1111/resp.13387"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_pm_t15":{
"id":"mk19_b_pm_t15",
"number":15,
"bookId":"pm",
"title":{
"__html":"Classification of Diffuse Parenchymal Lung Disease"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"bbcf6f",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 15. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t15"
}
]
},
"Classification of Diffuse Parenchymal Lung Disease"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ddffd6",
"class":"col hd l",
"children":[
"Known Causes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"297c95",
"class":"cell txt l",
"children":[
"Drug-induced"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c020d5",
"class":"cell txt l",
"children":[
"Examples: amiodarone, methotrexate, nitrofurantoin, chemotherapeutic agents (see ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.pneumotox.com/",
"target":"_blank"
},
"children":[
"www.pneumotox.com/"
]
},
" for a complete listing)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0df02",
"class":"cell txt l",
"children":[
"Smoking-related"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21fb14",
"class":"cell txt l",
"children":[
"Respiratory bronchiolitis-associated ILD, desquamative interstitial pneumonia, smoking-related pulmonary fibrosis, combined emphysema with pulmonary fibrosis, pulmonary Langerhans cell histiocytosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bff9b6",
"class":"cell txt l",
"children":[
"Radiation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64adfb",
"class":"cell txt l",
"children":[
"Radiation-induced lung injury, radiation pneumonitis/radiation fibrosis; may occur weeks to months after radiation therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"500cb7",
"class":"cell txt l",
"children":[
"Chronic aspiration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9ddbe",
"class":"cell txt l",
"children":[
"Aspiration is often subclinical and may exacerbate other forms of DPLD, mainly in the lower lobes; focal consolidation on CT scan of the chest, usually predominantly the right side"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ff732",
"class":"cell txt l",
"children":[
"Pneumoconioses"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f26b6c",
"class":"cell txt l",
"children":[
"Asbestosis, silicosis, berylliosis, coal workers' pneumoconiosis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"320566",
"class":"cell txt l",
"children":[
"Connective tissue diseases (RA, systemic sclerosis, dermatomyositis, polymyositis, MCTD, SLE, Sjögren syndrome)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"658f2d",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia, organizing pneumonia, usual interstitial pneumonia, lymphocytic interstitial pneumonia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"79cd44",
"class":"cell txt l",
"children":[
"Hypersensitivity pneumonitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4fc225",
"class":"cell txt l",
"children":[
"Acute, subacute, or chronic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd3c46",
"class":"col hd l",
"children":[
"Unknown Causes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f0f133",
"class":"cell txt l",
"children":[
"Idiopathic interstitial pneumonias"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"92dc6b",
"class":"cell txt li",
"children":[
"Idiopathic pulmonary fibrosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744801",
"class":"cell txt l",
"children":[
"Chronic, insidious onset of cough and dyspnea, usually in a patient aged >50 years; usual interstitial pneumonia pathology (honeycombing, bibasilar infiltrates with fibrosis); diagnosis of exclusion"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"03c991",
"class":"cell txt li",
"children":[
"Idiopathic nonspecific interstitial pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b37eb",
"class":"cell txt l",
"children":[
"Affects a younger population than IPF; honeycombing is uncommon on HRCT"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"911d74",
"class":"cell txt li",
"children":[
"Cryptogenic organizing pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2c86d",
"class":"cell txt l",
"children":[
"Subacute presentation, patchy opacities that mimic infectious pneumonia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8d6db",
"class":"cell txt li",
"children":[
"Acute interstitial pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2261b7",
"class":"cell txt l",
"children":[
"Rapid progression to respiratory failure; high mortality"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c57e04",
"class":"cell txt l",
"children":[
"Sarcoidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6c1fe",
"class":"cell txt l",
"children":[
"Variable clinical presentation, ranging from asymptomatic to multiorgan involvement: stage 1, hilar lymphadenopathy; stage 2, hilar lymphadenopathy plus interstitial lung disease; stage 3, interstitial lung disease; stage 4, fibrosis. Noncaseating granulomas are hallmark."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a11778",
"class":"col hd l",
"children":[
"Rare DPLD With Well-Defined Features"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7149a5",
"class":"cell txt l",
"children":[
"Lymphangioleiomyomatosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51f9ca",
"class":"cell txt l",
"children":[
"Affects women, usually in their 30s and 40s. Associated with spontaneous pneumothorax and chylous effusions. Chest CT scan shows cystic disease that is diffuse in distribution."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"609a34",
"class":"cell txt l",
"children":[
"Chronic eosinophilic pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1cc2b",
"class":"cell txt l",
"children":[
"Chest radiograph shows “radiographic negative” heart failure, with peripheral alveolar infiltrates predominating. Other findings may include peripheral blood eosinophilia and eosinophilia on bronchoalveolar lavage >25%."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"79911c",
"class":"cell txt l",
"children":[
"Pulmonary alveolar proteinosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5c283a",
"class":"cell txt l",
"children":[
"Median age 39 years. Males predominate among smokers, but not nonsmokers. Diagnosed using bronchoalveolar lavage, which shows proteinaceous material in and around alveolar macrophages (periodic acid-Schiff stain positive). Chest CT scan shows “crazy paving” pattern."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DPLD = diffuse parenchymal lung disease; HRCT = high-resolution CT; ILD = interstitial lung disease; IPF = idiopathic pulmonary fibrosis; MCTD = mixed connective tissue disease; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus."
]
]
},
"mk19_b_pm_t16":{
"id":"mk19_b_pm_t16",
"number":16,
"bookId":"pm",
"title":{
"__html":"Patterns of Disease Associated With a Diagnosis of Diffuse Parenchymal Lung Disease"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"8eca31",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 16. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t16"
}
]
},
"Patterns of Disease Associated With a Diagnosis of Diffuse Parenchymal Lung Disease"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"430b17",
"class":"col hd l",
"children":[
"Lung Disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"92c65a",
"class":"col hd l",
"children":[
"Imaging"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8d6db",
"class":"cell txt l",
"children":[
"Acute interstitial pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb924f",
"class":"cell txt l",
"children":[
"Diffuse ground glass with consolidation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52d80c",
"class":"cell txt l",
"children":[
"Indistinguishable from ARDS but without a risk factor for ARDS"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b169c1",
"class":"cell txt l",
"children":[
"Organizing pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d151cf",
"class":"cell txt l",
"children":[
"Patchy ground glass, alveolar consolidation, peripheral and basal predominance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c22c3",
"class":"cell txt l",
"children":[
"Connective tissue diseases, infections, drug-related, or idiopathic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b3febd",
"class":"cell txt l",
"children":[
"Idiopathic pulmonary fibrosis/usual interstitial pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cb2623",
"class":"cell txt l",
"children":[
"Basal-predominant and peripheral-predominant septal line thickening with traction bronchiectasis and honeycomb changes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b38975",
"class":"cell txt l",
"children":[
"Usual interstitial pneumonia pattern can be seen in connective tissue disease, asbestosis, and chronic hypersensitivity pneumonitis; idiopathic pulmonary fibrosis is diagnosis of exclusion"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f14566",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46dd6d",
"class":"cell txt l",
"children":[
"Ground glass, basal predominance"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4fbac5",
"class":"cell txt l",
"children":[
"Idiopathic and common finding in connective tissue disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6f5e7",
"class":"cell txt l",
"children":[
"Respiratory bronchiolitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"12a9bb",
"class":"cell txt l",
"children":[
"Centrilobular nodules and ground-glass opacity in an upper-lung-predominant distribution"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65a703",
"class":"cell txt l",
"children":[
"May be an asymptomatic finding in an active smoker"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7fb15d",
"class":"cell txt l",
"children":[
"Desquamative interstitial pneumonia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b36de7",
"class":"cell txt l",
"children":[
"Basal-predominant and peripheral-predominant ground-glass opacity with occasional cysts"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e73ec",
"class":"cell txt l",
"children":[
"Most cases are smoking related; chest radiograph may be normal in 20%, but HRCT demonstrates ground-glass opacities"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"79cd44",
"class":"cell txt l",
"children":[
"Hypersensitivity pneumonitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15a730",
"class":"cell txt l",
"children":[
"Acute: ground-glass opacification; centrilobular micronodules that are upper- and mid-lung-predominant"
]
},
" ",
{
"type":"p",
"hlId":"1ff6ad",
"class":"cell txt l",
"children":[
"Chronic: mid-lung- and upper-lung-predominant septal lung thickening with traction bronchiectasis; usual interstitial pneumonia pattern may be seen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"846197",
"class":"cell txt l",
"children":[
"Acute: associated with flulike illness"
]
},
" ",
{
"type":"p",
"hlId":"eda245",
"class":"cell txt l",
"children":[
"Chronic: often cannot identify a causative antigen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c57e04",
"class":"cell txt l",
"children":[
"Sarcoidosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e2f01",
"class":"cell txt l",
"children":[
"Upper-lobe-predominant; mediastinal and hilar lymphadenopathy; cystic changes, including development of aspergilloma; small nodules oriented along bronchovascular bundles"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6bd24d",
"class":"cell txt l",
"children":[
"Findings for sarcoidosis often not specific; DPLD with diffuse mediastinal and hilar lymphadenopathy greater than 2 cm in size should raise suspicion"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ARDS = acute respiratory distress syndrome; DPLD = diffuse parenchymal lung disease; HRCT = high-resolution CT scan."
]
]
},
"mk19_b_pm_t17":{
"id":"mk19_b_pm_t17",
"number":17,
"bookId":"pm",
"title":{
"__html":"Connective Tissue Diseases Associated With Diffuse Parenchymal Lung Disease"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"dde858",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 17. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t17"
}
]
},
"Connective Tissue Diseases Associated With Diffuse Parenchymal Lung Disease"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9014e",
"class":"col hd l",
"children":[
"Connective Tissue Disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"857494",
"class":"col hd l",
"children":[
"Typical DPLD Patterns and Associated Pulmonary Manifestations"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a24b15",
"class":"cell txt l",
"children":[
"Rheumatoid arthritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"250515",
"class":"cell txt l",
"children":[
"Usual interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"f14566",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"b169c1",
"class":"cell txt l",
"children":[
"Organizing pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"70c982",
"class":"cell txt l",
"children":[
"Rheumatoid nodules"
]
},
" ",
{
"type":"p",
"hlId":"19c04e",
"class":"cell txt l",
"children":[
"Other pulmonary manifestations: pleuritis and pleural effusion, airway disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52b7c1",
"class":"cell txt l",
"children":[
"Systemic sclerosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f14566",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"378fe3",
"class":"cell txt l",
"children":[
"Other pulmonary manifestations: pulmonary hypertension, aspiration from esophageal dysmotility"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a4d69",
"class":"cell txt l",
"children":[
"Polymyositis/dermatomyositis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f14566",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"b169c1",
"class":"cell txt l",
"children":[
"Organizing pneumonia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32ee95",
"class":"cell txt l",
"children":[
"Systemic lupus erythematosus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f14566",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"b169c1",
"class":"cell txt l",
"children":[
"Organizing pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"a08582",
"class":"cell txt l",
"children":[
"Lymphocytic interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"968b19",
"class":"cell txt l",
"children":[
"Other pulmonary manifestations: acute pneumonitis, pulmonary hemorrhage, pleuritis, thromboembolic disease, pulmonary hypertension, shrinking lung syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ecc1e2",
"class":"cell txt l",
"children":[
"Sjögren syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f14566",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"a08582",
"class":"cell txt l",
"children":[
"Lymphocytic interstitial pneumonia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfb1bd",
"class":"cell txt l",
"children":[
"Mixed connective tissue disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f14566",
"class":"cell txt l",
"children":[
"Nonspecific interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"b169c1",
"class":"cell txt l",
"children":[
"Organizing pneumonia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"156e4e",
"class":"cell txt l",
"children":[
"ANCA-associated vasculitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"250515",
"class":"cell txt l",
"children":[
"Usual interstitial pneumonia"
]
},
" ",
{
"type":"p",
"hlId":"2e8a2c",
"class":"cell txt l",
"children":[
"Less commonly, nonspecific interstitial pneumonia"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ANCA = antineutrophil cytoplasmic antibody; DPLD = diffuse parenchymal lung disease."
]
]
},
"mk19_b_pm_t18":{
"id":"mk19_b_pm_t18",
"number":18,
"bookId":"pm",
"title":{
"__html":"Selected Drug-Induced Parenchymal Lung Diseases"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"29b025",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 18. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t18"
}
]
},
"Selected Drug-Induced Parenchymal Lung Diseases"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43e754",
"class":"col hd l",
"children":[
"Clinical Points"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea67d7",
"class":"col hd l",
"children":[
"Radiographic Findings and Treatment"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fccce3",
"class":"cell txt l",
"children":[
"Amiodarone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e344a7",
"class":"cell txt l",
"children":[
"More common in:"
]
},
" ",
{
"type":"p",
"hlId":"dd2ff2",
"class":"cell txt li",
"children":[
"Older patients"
]
},
" ",
{
"type":"p",
"hlId":"55ca45",
"class":"cell txt li",
"children":[
"Increased dosage and higher cumulative dose"
]
},
" ",
{
"type":"p",
"hlId":"769290",
"class":"cell txt li",
"children":[
"First year of therapy (but can occur late)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c56efc",
"class":"cell txt l",
"children":[
"Multiple radiographic presentations possible, including ground-glass opacities, subpleural nodules, and reticular abnormalities"
]
},
" ",
{
"type":"p",
"hlId":"0e1c56",
"class":"cell txt l",
"children":[
"Very long half-life prevents clearance from the pulmonary parenchyma:"
]
},
" ",
{
"type":"p",
"hlId":"a6215c",
"class":"cell txt li",
"children":[
"Rare improvement with discontinuation of the drug alone"
]
},
" ",
{
"type":"p",
"hlId":"04f86b",
"class":"cell txt li",
"children":[
"High risk for recurrence with tapering of glucocorticoids"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98cff",
"class":"cell txt l",
"children":[
"Methotrexate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"418d6b",
"class":"cell txt l",
"children":[
"Occurs in less than 5% of treated patients"
]
},
" ",
{
"type":"p",
"hlId":"49ec29",
"class":"cell txt l",
"children":[
"Unpredictable time to presentation"
]
},
" ",
{
"type":"p",
"hlId":"b4fc64",
"class":"cell txt l",
"children":[
"No clear correlation between dose and disease severity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6a4f4",
"class":"cell txt l",
"children":[
"Diffuse reticular and ground-glass attenuation"
]
},
" ",
{
"type":"p",
"hlId":"ac3f0e",
"class":"cell txt l",
"children":[
"Patients generally do well after stopping medication"
]
},
" ",
{
"type":"p",
"hlId":"f0010c",
"class":"cell txt l",
"children":[
"Glucocorticoids are often given; duration is based on response"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc99ce",
"class":"cell txt l",
"children":[
"Nitrofurantoin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37c935",
"class":"cell txt l",
"children":[
"Acute (more common):"
]
},
" ",
{
"type":"p",
"hlId":"327f96",
"class":"cell txt li",
"children":[
"Fevers, chills, cough, shortness of breath, chest pain; rash can occur in 10%-20% of patients"
]
},
" ",
{
"type":"p",
"hlId":"c744cb",
"class":"cell txt li",
"children":[
"Peripheral eosinophilia common"
]
},
" ",
{
"type":"p",
"hlId":"5e0187",
"class":"cell txt l",
"children":[
"Chronic:"
]
},
" ",
{
"type":"p",
"hlId":"8d454a",
"class":"cell txt li",
"children":[
"Distinct from the acute form"
]
},
" ",
{
"type":"p",
"hlId":"3dcf62",
"class":"cell txt li",
"children":[
"Onset months to years after prolonged exposure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5a66b",
"class":"cell txt l",
"children":[
"Acute: Faint bilateral lower lobe septal lines; moderate pleural effusions may be present; often resolves with discontinuation but will recur with repeat exposure"
]
},
" ",
{
"type":"p",
"hlId":"00a277",
"class":"cell txt l",
"children":[
"Chronic: Reticular opacities with subpleural lines and thickened peri-bronchovascular areas; possible benefit of glucocorticoids from anecdotal reports"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6036f5",
"class":"cell txt l",
"children":[
"Busulfan"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c8a21",
"class":"cell txt l",
"children":[
"Occurs in less than 8% of treated patients"
]
},
" ",
{
"type":"p",
"hlId":"da001c",
"class":"cell txt l",
"children":[
"Currently used solely as a preparative regimen for HSCT; often combined with other agents associated with pulmonary toxicity"
]
},
" ",
{
"type":"p",
"hlId":"d58248",
"class":"cell txt l",
"children":[
"Injury typically occurs 30 days to 1 year after exposure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34b5f9",
"class":"cell txt l",
"children":[
"Multiple patterns, including ground-glass opacities, reticulation, bibasilar septal lines, asymmetric peripheral and peribronchial consolidation, centrilobular nodules, and dependent consolidation"
]
},
" ",
{
"type":"p",
"hlId":"75c7af",
"class":"cell txt l",
"children":[
"Optimal treatment unknown and is often supportive"
]
},
" ",
{
"type":"p",
"hlId":"957ff0",
"class":"cell txt l",
"children":[
"Glucocorticoids may be used for more progressive disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31e2ec",
"class":"cell txt l",
"children":[
"Bleomycin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7e31a",
"class":"cell txt l",
"children":[
"Risk significantly increases with cumulative dose"
]
},
" ",
{
"type":"p",
"hlId":"fd54cb",
"class":"cell txt l",
"children":[
"Increased age, kidney disease, concomitant chemotherapy or irradiation also increase risk for toxicity"
]
},
" ",
{
"type":"p",
"hlId":"0d9efe",
"class":"cell txt l",
"children":[
"Typically subacute presentation 1-6 months after exposure; may show hypersensitivity pneumonitis, diffuse alveolar damage, or usual interstitial pneumonia pathologically but with more rapid clinical onset and progressive course"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"180863",
"class":"cell txt l",
"children":[
"Imaging patterns suggest the multiple possible pathologic findings seen:"
]
},
" ",
{
"type":"p",
"hlId":"73ec94",
"class":"cell txt li",
"children":[
"Consolidation with ground glass (diffuse alveolar damage)"
]
},
" ",
{
"type":"p",
"hlId":"40b186",
"class":"cell txt li",
"children":[
"Septal line thickening, traction bronchiectasis, and honeycomb change (end-stage fibrosis)"
]
},
" ",
{
"type":"p",
"hlId":"b7815f",
"class":"cell txt li",
"children":[
"Patchy ground glass with subpleural consolidation or peribronchial consolidation (organizing pneumonia)"
]
},
" ",
{
"type":"p",
"hlId":"243201",
"class":"cell txt li",
"children":[
"Diffuse ground glass with centrilobular micronodules (hypersensitivity pneumonitis)"
]
},
" ",
{
"type":"p",
"hlId":"9954ab",
"class":"cell txt li",
"children":[
"Glucocorticoids used for more severe disease; disease may recur with tapering of steroids"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"HSCT = hematopoietic stem cell transplantation."
]
]
},
"mk19_b_pm_t19":{
"id":"mk19_b_pm_t19",
"number":19,
"bookId":"pm",
"title":{
"__html":"Chest Radiograph Staging of Pulmonary Sarcoidosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a0c5d4",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 19. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t19"
}
]
},
"Chest Radiograph Staging of Pulmonary Sarcoidosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64c6da",
"class":"col hd l",
"children":[
"Stage"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d776e3",
"class":"col hd l",
"children":[
"Radiographic Pattern"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57cc04",
"class":"col hd l",
"children":[
"Clinical Course and Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"960b44",
"class":"cell txt l",
"children":[
"Normal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd7536",
"class":"cell txt l",
"children":[
"I"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e48d7b",
"class":"cell txt l",
"children":[
"Hilar lymphadenopathy with normal lung parenchyma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"acb018",
"class":"cell txt l",
"children":[
">90% rate of spontaneous resolution without treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66cc12",
"class":"cell txt l",
"children":[
"II"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ad72c",
"class":"cell txt l",
"children":[
"Hilar lymphadenopathy with abnormal lung parenchyma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1c61d",
"class":"cell txt l",
"children":[
"Approximately 50% rate of spontaneous improvement without treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51ac45",
"class":"cell txt l",
"children":[
"III"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4dd04a",
"class":"cell txt l",
"children":[
"No lymphadenopathy with abnormal lung parenchyma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"381b27",
"class":"cell txt l",
"children":[
"Approximately 20% rate of spontaneous improvement without treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf482c",
"class":"cell txt l",
"children":[
"IV"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"809ba3",
"class":"cell txt l",
"children":[
"Parenchymal changes with fibrosis and architectural distortion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_pm_t20":{
"id":"mk19_b_pm_t20",
"number":20,
"bookId":"pm",
"title":{
"__html":"Clinical Presentations of Sarcoidosis That Do Not Require a Biopsy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"26d78b",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 20. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t20"
}
]
},
"Clinical Presentations of Sarcoidosis That Do Not Require a Biopsy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48d8d6",
"class":"col hd l",
"children":[
"Syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e28b3d",
"class":"col hd l",
"children":[
"Additional Findings/Symptoms"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d9e80",
"class":"cell txt l",
"children":[
"Asymptomatic bilateral hilar lymphadenopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e679c",
"class":"cell txt l",
"children":[
"No evidence of fevers, malaise, or night sweats to suggest a malignancy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1a071",
"class":"cell txt l",
"children":[
"Löfgren syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f96d98",
"class":"cell txt l",
"children":[
"Bilateral hilar lymphadenopathy, migratory polyarthralgia, erythema nodosum, and fever"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98d373",
"class":"cell txt l",
"children":[
"Heerfordt syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8879f1",
"class":"cell txt l",
"children":[
"Anterior uveitis, parotitis, fever (uveoparotid fever), and facial nerve palsy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}